mTBI Identification and Monitoring Through Retinal Scanning
Condition(s) studied
Investigational drug(s) / intervention(s)
Head and Intraocular Trauma Tool: HITT device to scan the eyes of participants up to 3 times (\~45 seconds each) at the time of admittance to study. The participant is to place the chin in the chin-rest and fixate on the illuminated light on the device.
Study summary
Rebion has developed a device, the Rebion trauma tool (referred to as the head and intraocular trauma tool, or "HITT"), that detects ocular fixation and alignment using a binocular retinal scan. Preliminary data obtained from hospitalized patients with a clinically-confirmed traumatic brain injury (TBI) and uninjured controls indicates that the device can detect changes in ocular fixation, alignment, and saccades that are related to brain injury. This study seeks to evaluate the ability of the Rebion trauma tool to assess perturbations in eye movements resulting from TBI. The study will enroll 60 TBI patients and 20 controls.
Eligibility
Primary outcome measure(s)
- TBI Detection — 1 day
Patients who present with suspected TBI to the clinic will have their eyes scanned to identify whether the HITT device can accurately identify patients with TBI.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Boston Medical Center Concussion Clinic, Ryan Center for Sports Medicine & Rehabilitation at Boston University | Boston | Massachusetts | Recruiting |
More Rebiscan, Inc. trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06142435 on ClinicalTrials.gov ↗ ← All trials in the USA